论文信息 - Cervix cancer. Treatment with combination vincristine and high doses of methotrexate

Cervix cancer. Treatment with combination vincristine and high doses of methotrexate

Patients with carcinoma of the cervix (31) and of the vulva (2) were treated with high doses of Methotrexate. The objective response rate was 17% with a median duration of 3 months. Three toxic deaths occurred. The response rate of high dose methotrexate in advanced and prior treated cervix cancer does not differ from that reported in prior studies with conventional doses of intravenous methotrexate. Cancer 43:459–464, 1979.

G. Magill | T. Hakes | M. Ochoa | M. Nikrui

[1] S. Rosenberg,et al. Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate , 1978, Cancer.

[2] S. Rosenberg,et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.

[3] S. Carter,et al. The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. , 1977, Cancer treatment reviews.

[4] Steer Pj. Letter: Obstetric delivery today. , 1976, Lancet.

[5] V. Oliverio,et al. The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. , 1973, Cancer research.

[6] J. Cassady,et al. Favorable response of metastatic osteogenic sarcoma to pulse high‐dose methotrexate with citrovorum rescue and radiation therapy , 1973, Cancer.

[7] Jung Sun Kim,et al. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer , 1972, Cancer.

[8] R. Trussell,et al. Carcinoma of the cervix treated with continuous intra-arterial methotrexate and intermittent intramuscular leucovorin. , 1961, Lancet.

[9] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .